Genome Editing Market to Reach $13.36 Billion by 2035, Growing at 10.8% CAGR | CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine Among Key Players

The global genome editing market, valued at $4.25 billion in 2025 and projected to reach $5.29 billion in 2026, is on track to hit $13.36 billion by 2035, advancing at a compound annual growth rate of 10.8% over the forecast period. The acceleration reflects intensifying pharmaceutical investment in CRISPR-based therapies, a surge in licensing agreements between technology developers and drug makers, and a regulatory environment that is steadily becoming more accommodating of gene-edited therapeutics. For investors, biopharmaceutical executives, and technology developers, the numbers signal a decade-long commercial opportunity that is only beginning to take shape.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/genome-editing-market/request-sample.html

MARKET OVERVIEW
Genome editing, the precise modification of an organism's DNA through insertion, deletion, or replacement of specific nucleotide sequences, has moved from an academic curiosity to a central pillar of next-generation drug development. Tools including CRISPR-Cas systems, TALENs, meganucleases, and zinc finger nucleases now give researchers the ability to correct faulty genes underlying conditions such as sickle cell disease, Parkinson's disease, spinal muscular atrophy, and a range of hematological disorders. The World Health Organization estimates that 10 out of every 1,000 individuals worldwide are affected by genetic disorders, with more than 70 million people living with such conditions and over 40% of global infant mortality linked to genetic disease. That disease burden creates an enormous addressable market for companies developing precise, durable genetic interventions.

The industry's momentum is reinforced by capital and clinical evidence arriving simultaneously. More than $14 billion in cumulative funding has flowed into genome editing since 2018, the majority via venture capital rounds. Intellia Therapeutics alone raised $648.3 million through a secondary offering. On the clinical side, more than 1,100 active trials are currently evaluating gene therapies across all phases of development. In June 2024, the FDA signaled its intent to introduce a platform designation program specifically designed to ease the regulatory path for gene-editing therapies, a step that will lower the cost and time burden for companies moving multiple candidates through the pipeline.

Strategic deal-making is also accelerating. Since 2018, technology providers in the genome editing space have signed more than 260 partnerships covering technology licensing, R&D collaboration, and product development. In 2024 alone, 35% of all new agreements were technology licensing deals, reflecting a commercial model where technology developers monetize their platforms without bearing the full cost of clinical development. Recent examples include agreements between ERS Genomics and the Université de Montréal, Medicines Discovery Catapult, and IRBM, all completed within a five-month window in 2024.

KEY GROWTH DRIVERS
CRISPR adoption is pulling the market. CRISPR-Cas systems currently account for 84% of all genome editing technologies in active development. The shift to next-generation variants, specifically base editing and prime editing, is extending CRISPR's utility by enabling more precise single-base corrections without the double-strand breaks associated with earlier tools. Industry stakeholders cited the potential for CRISPR to reduce the cost of genetic testing and disease detection as a factor that will broaden adoption well beyond therapeutic applications.

Cell and gene therapy pipelines are multiplying. Cell therapies represent 65% of the current genome editing market, driven by their broader applicability across disease indications and the ability to introduce functional cells directly into patients. Gene therapies, while currently a smaller share, are attracting increasing attention as mRNA-based and CRISPR-based platforms demonstrate clinical viability. The pipeline continues to expand: in October 2024, Editas Medicine signed a technology integration agreement with Genevant Sciences to combine CRISPR Cas12a editing with Genevant's proprietary lipid nanoparticle delivery technology for in vivo gene editing medicines.

Technology out-licensing is generating recurring revenue. Ninety-six percent of genome editing technology providers operate on an out-licensing model, generating revenue through upfront payments and milestone structures. Currently, upfront payments account for 53% of the market; by 2035, milestone payments are projected to capture 62% of revenues as more licensed products advance through clinical stages and reach commercial approval.

Drug discovery and development is the dominant application. Gene editing technologies, particularly CRISPR, are widely deployed to identify novel drug targets and map the genetic basis of complex diseases. Drug discovery and development commands 85% of the application-area market today, with diagnostics projected to grow its share as genome editing tools prove their worth in early disease screening.

Start-up activity is broadening the technology base. Of the 110-plus companies active in the genome editing space, 57% were established after 2016. Recent entrants include Akribion Genomics, CorriXR Therapeutics, Nvelop Therapeutics, and Primera Therapeutics. This wave of new entrants is introducing novel delivery modalities, non-viral vector platforms, and specialized editing tools that incumbent players are increasingly licensing rather than developing in-house.

MARKET SEGMENTATION
The genome editing market segments across gene editing technique, therapy type, delivery method, delivery modality, application area, end-user, and geography. By technique, CRISPR-Cas systems dominate with 84% market share, while TALENs, ZFNs, and meganucleases occupy the remaining share. By delivery method, ex vivo approaches lead with 62% of the market, favored for their precision and lower off-target risk compared to direct in vivo administration. Viral vectors currently account for 55% of gene delivery modality revenue, though non-viral vectors are gaining ground rapidly as the field addresses immunogenicity and scale-up challenges associated with viral platforms.

Pharmaceutical and biotechnology companies account for 82% of end-user revenues, reflecting that roughly 90% of all technology licensing agreements in this space are inked with commercial drug developers. Academic and research institutes represent the remaining share, providing the early-stage validation and IP development that commercial players subsequently license. Drug discovery and development leads by application with 85% share, while the diagnostics segment is expected to see accelerating adoption as genome editing tools demonstrate precision and cost advantages in early disease screening.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/genome-editing-market/request-quote.html

REGIONAL INSIGHTS
North America holds approximately 75 to 80% of the global genome editing market, a dominance driven by the concentration of technology developers in the United States and Canada, the region's commanding share of total funding received since 2018, and the highest volume of technology licensing and integration agreements globally. Companies such as Mammoth Biosciences, Metagenomi, and Vor Biopharma, all mid-sized North American players focused on base editing, exemplify the breadth of the region's commercial activity.

Europe is home to a growing cohort of genome editing firms, with Germany, France, and Ireland serving as the primary hubs. The region's strength lies in academic-to-commercial technology transfer, with institutions such as the Université de Montréal actively licensing genome editing intellectual property to commercial developers. Asia-Pacific, anchored by South Korea, China, and Japan, represents the market's fastest-growing regional segment, supported by expanding biotech infrastructure, government investment in genetic medicine, and a growing number of domestic gene therapy clinical programs.

COMPETITIVE LANDSCAPE
Key companies profiled in the genome editing market include Arcturus Therapeutics, ArsenalBio, Avectas, Beam Therapeutics, Bio-Sourcing, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Editas Medicine, Flash Biosolutions, Graphite Bio, Intellia Therapeutics, NTrans Technologies, OXGENE, Prime Medicine, Revvity, and Vor Biopharma, among more than 110 companies covered in the full report.

The market is concentrated but highly active, with established players defending IP positions through an aggressive licensing model while a new generation of post-2016 startups introduces competing platforms. The primary competitive battleground is technology differentiation: the ability to offer higher editing precision, lower immunogenicity, and scalable manufacturing is increasingly the deciding factor in licensing negotiations. Mergers and acquisitions remain a tool for established players to acquire novel delivery platforms, and the volume of strategic alliances suggests that consolidation will accelerate as clinical programs approach commercialization.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/genome-editing-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.